146 related articles for article (PubMed ID: 38329775)
1. The quest for a cure in follicular lymphoma.
Tonino SH; Kersten MJ
Blood; 2024 Feb; 143(6):475-476. PubMed ID: 38329775
[No Abstract] [Full Text] [Related]
2. Giant follicular lymphoblastoma: its treatment with radioisotopes.
LAWRENCE JH; DONALD WG
Ann Intern Med; 1958 Jul; 49(1):1-16. PubMed ID: 13545729
[No Abstract] [Full Text] [Related]
3. [Treatment of malignant low-grade lymphoma. Follicular Lymphoma Study Group].
Solal-Celigny P
Rev Med Interne; 1998; 19 Suppl 1():18S-20S. PubMed ID: 9789523
[No Abstract] [Full Text] [Related]
4. [CAR-T cells in lymphomas: Current and evolving role].
Messéant O; Houot R
Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
[TBL] [Abstract][Full Text] [Related]
5. C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.
Jacobson CA; Maus MV
Blood Adv; 2020 Nov; 4(22):5858-5862. PubMed ID: 33232481
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.
Kharfan-Dabaja MA; Jain MD; Aulakh S; Ayala E; Zubair AC; Tun HW; Liu HD; Locke FL; Chavez JC
Am J Hematol; 2019 Sep; 94(9):E245-E247. PubMed ID: 31211433
[No Abstract] [Full Text] [Related]
7. Transformed follicular non-Hodgkin lymphoma.
Casulo C; Burack WR; Friedberg JW
Blood; 2015 Jan; 125(1):40-7. PubMed ID: 25499449
[TBL] [Abstract][Full Text] [Related]
8. [Current status of therapy of follicular germ center lymphoma and mantel cell lymphoma].
Hiddemann W; Unterhalt M; Sack H
Internist (Berl); 1997 Feb; 38(2):122-34. PubMed ID: 9157057
[No Abstract] [Full Text] [Related]
9. CAR-T for follicular lymphoma: are we good to go?
Gasiorowski R; Trotman J
Blood; 2022 Aug; 140(8):799-800. PubMed ID: 36006675
[No Abstract] [Full Text] [Related]
10. Lymphosarcoma. Treatment and end results in 355 patients.
Molander DW
Am J Roentgenol Radium Ther Nucl Med; 1973 Jan; 117(1):54-8. PubMed ID: 4119564
[No Abstract] [Full Text] [Related]
11. Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.
Brown KS; Levitt DJ; Shannon M; Link BK
Clin Lymphoma; 2001 Dec; 2(3):188-90. PubMed ID: 11779298
[No Abstract] [Full Text] [Related]
12. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
Cohen JA; Ghobadi A
Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
[TBL] [Abstract][Full Text] [Related]
13. Low-grade follicular lymphoma of the small intestine: a challenge for management.
Bennani-Baiti N; Daw HA; Cotta C; Martin P; Mitchell KW; Ambinder RF; Macklis R; Pollock R; Spiro T
Semin Oncol; 2011 Dec; 38(6):714-20. PubMed ID: 22082756
[No Abstract] [Full Text] [Related]
14. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Berglund A; Enblad G; Carlson K; Glimelius B; Hagberg H
Eur J Haematol; 2000 Jul; 65(1):17-22. PubMed ID: 10914935
[TBL] [Abstract][Full Text] [Related]
15. [The use of nitrogen mustard in the treatment of lymphatic diseases of a malignant type].
RABENKO J; CORREA URQUIZA LM
Prensa Med Argent; 1959 Oct; 46():2549-54. PubMed ID: 14435621
[No Abstract] [Full Text] [Related]
16. The evolving use of CAR T-cell therapy in follicular lymphoma.
Nastoupil LJ
Clin Adv Hematol Oncol; 2021 Nov; 19(11):684-686. PubMed ID: 34807012
[No Abstract] [Full Text] [Related]
17. [Malignant lymphoma. Physiopathology and treatment. 2. Lymphoma of low grade malignancy].
Kobayashi Y
Nihon Naika Gakkai Zasshi; 2008 Jul; 97(7):1581-7. PubMed ID: 18720599
[No Abstract] [Full Text] [Related]
18. Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience.
Tezcan H; Vose JM; Bast M; Bierman PJ; Kessinger A; Armitage JO
Leuk Lymphoma; 1999 Jul; 34(3-4):273-85. PubMed ID: 10439364
[TBL] [Abstract][Full Text] [Related]
19. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
